Recruiting studies: Driver Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT
Phase 3 · 1 location(s) · Tata Memorial Hospital · NCT05236946 Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC
Phase N/A · 1 location(s) · Hunan Province Tumor Hospital · NCT04324151 A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Su
Phase 1 · 1 location(s) · Boryung Pharmaceutical Co., Ltd · NCT07069335 Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutation
Phase N/A · 2 location(s) · University of Colorado, Denver · NCT03958565 Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC
Phase 2 · 1 location(s) · Tata Memorial Hospital · NCT05277844 Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Active Brain Metastasis
Phase 2 · 1 location(s) · Fudan University · NCT06501378 InheriteD brEast caNcer iTalian regIsTrY A Retrospective-prospective Observational Cohort Study to Evaluate Cancer Preve
Phase N/A · 12 location(s) · Centro di Riferimento Oncologico - Aviano · NCT05835739 Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomark
NA · 25 location(s) · Institut Claudius Regaud · NCT05378204 A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer
Phase 2 · 5 location(s) · Suzhou BlueHorse Therapeutics Co., Ltd. · NCT07444437 ProSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors (START-TKI)
Phase N/A · 1 location(s) · Erasmus Medical Center · NCT05221372 Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X)
Phase 2 · 1 location(s) · Medical College of Wisconsin · NCT06305715 Lung Cancer Screening of Family Members of Patients With Mutation-Driven Lung Cancer
NA · 1 location(s) · University of California, Irvine · NCT07062172 DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-
Phase N/A · 7 location(s) · AstraZeneca · NCT07109154 Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis
Phase 2 · 1 location(s) · Fudan University · NCT06501391 Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
Phase 2 · 1 location(s) · Guangdong Provincial People's Hospital · NCT05800340 Prophylactic Irradiation to the Contralateral Breast for BCAs Patients
NA · 8 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT04960839 Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcin
Phase 2 · 1 location(s) · Hunan Cancer Hospital · NCT07314216 Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally
Phase N/A · 1 location(s) · Guangdong Association of Clinical Trials · NCT07696832

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.